Vir Biotechnology Inc VIR
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-10-11 |
| Shares Out. | 168,650,000 |
| Website | vir.bio/ ↗ |
| Phone | 14159064324 |
| Employees | 367 |
| Revenue | -$29,000 |
| Gross Profit | -$29,000 |
| Net Income | -$125.7M |
| Free Cash Flow | -$449.6M |
| Total Assets | $1.03B |
| Total Liabilities | $212.8M |
| Equity | $812.8M |
About Vir Biotechnology Inc
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Vir Biotechnology Inc is a publicly traded company under the ticker symbol VIR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)